newsroom.csl6d
Swissmedic Approves CSL Behring’s ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
ANDEMBRY® is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in HAE patients. The approval marks the fifth regulatory approval of ...
Livewire Markets14d
CSL’s mixed half-year: plasma strength offsets vaccine weakness, bright outlook maintained
When CSL acquired Vifor, it raised eyebrows, given initial integration hurdles and generic competition for some Vifor ...
stockhead15d
Dr Boreham’s Crucible: What’s all the fuss about biotech behemoth CSL?
While still robust, CSL half-year results last Weds revealed impact of an “alarming” fall off in 'flu vax rates, especially ...
Hosted on MSN19d
Has CSL lost its shine as the market's favourite growth story?
CSL shares tumbled 4.95% on the day of its half-year results after revenue, net profits and dividends missed market expectations Behring and Vifor outperformed, while Seqirus underperformed due to ...
Falling US flu vaccine rates hurt Australia's CSL profit growth
Australian biopharmaceutical company CSL said on Tuesday that falling immunisation rates in the U.S., its largest market, weighed on its vaccine sales and first-half profit growth, sending its shares ...